CAMBRIDGE, Mass., April 30, 2019 /PRNewswire/ -- Infinity
Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on
Tuesday, May 7, at 4:30 p.m. ET to review its first quarter 2019
financial results and provide an update on the company.
A live webcast of the conference call can be accessed in the
Investors/Media section of Infinity's website at www.infi.com. To
participate in the conference call, please dial 1-877-316-5293
(domestic) and 1-631-291-4526 (international) five minutes prior to
start time. The conference ID number is 5779562. An archived
version of the webcast will be available on Infinity's website for
30 days.
About Infinity and IPI-549
Infinity is an innovative biopharmaceutical company dedicated to
advancing novel medicines for people with cancer. Infinity is
advancing IPI-549, a first-in-class, oral immuno-oncology
development candidate that selectively inhibits PI3K-gamma, in
multiple clinical studies. MARIO-1 is an ongoing Phase
1/1b study evaluating IPI-549 as a
monotherapy and in combination with Opdivo (nivolumab) in
approximately 225 patients with advanced solid tumors including
patients refractory to anti-PD-1 therapy. Infinity intends to
initiate MARIO-275, a global, randomized, combination study of
IPI-549 combined with Opdivo in I/O naïve urothelial cancer
patients in 2Q19, as well as to initiate MARIO-3, the first IPI-549
combination study in front-line advanced cancer patients in 2H19.
MARIO-3 will evaluate IPI-549 in combination with Tecentriq and
Abraxane in front-line TNBC and in combination with Tecentriq and
Avastin in front-line RCC. With the addition of MARIO-275 and
MARIO-3 to the ongoing MARIO-1 study, Infinity will be evaluating
IPI-549 in the anti-PD-1 refractory, I/O-naïve and front-line
settings in a total of ~500 patients. For more information on
Infinity, please refer to Infinity's website
at www.infi.com.
Contact:
Stephanie
Ascher, Stern Investor Relations, Inc.
212-362-1200 or Stephanie@sternir.com
View original
content:http://www.prnewswire.com/news-releases/infinity-announces-the-date-of-its-first-quarter-2019-financial-results-conference-call-and-webcast-300840294.html
SOURCE Infinity Pharmaceuticals, Inc.